218 related articles for article (PubMed ID: 28775174)
1. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
[TBL] [Abstract][Full Text] [Related]
2. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
3. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
Hwang HS; Yoon DH; Hong JY; Park CS; Lee YS; Ko YH; Kim SJ; Kim WS; Suh C; Huh J
Ann Hematol; 2018 Dec; 97(12):2363-2372. PubMed ID: 30069703
[TBL] [Abstract][Full Text] [Related]
4. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature.
Lee J; Hue SS; Ko SQ; Tan SY; Liu X; Girard LP; Chan EHL; De Mel S; Jeyasekharan A; Chee YL; Koh LP; Poon LM
Expert Rev Hematol; 2019 Dec; 12(12):1095-1105. PubMed ID: 31592693
[No Abstract] [Full Text] [Related]
6. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
8. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series.
Zamò A; Gerhard-Hartmann E; Ott G; Anagnostopoulos I; Scott DW; Rosenwald A; Rauert-Wunderlich H
Virchows Arch; 2022 Dec; 481(6):935-943. PubMed ID: 36219238
[TBL] [Abstract][Full Text] [Related]
9. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
[TBL] [Abstract][Full Text] [Related]
11. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.
Perfecto-Avalos Y; Garcia-Gonzalez A; Hernandez-Reynoso A; Sánchez-Ante G; Ortiz-Hidalgo C; Scott SP; Fuentes-Aguilar RQ; Diaz-Dominguez R; León-Martínez G; Velasco-Vales V; Cárdenas-Escudero MA; Hernández-Hernández JA; Santos A; Borbolla-Escoboza JR; Villela L
J Transl Med; 2019 Jun; 17(1):198. PubMed ID: 31185999
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
[TBL] [Abstract][Full Text] [Related]
13. Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.
Reinke S; Richter J; Fend F; Feller A; Hansmann ML; Hüttl K; Oschlies I; Ott G; Möller P; Rosenwald A; Stein H; Altenbuchinger M; Spang R; Klapper W
Virchows Arch; 2018 Sep; 473(3):341-349. PubMed ID: 29730836
[TBL] [Abstract][Full Text] [Related]
14. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Balasubramanian S; Wang S; Major C; Hodkinson B; Schaffer M; Sehn LH; Johnson P; Zinzani PL; Carey J; Shreeve SM; Sun S; Gerecitano J; Vermeulen J; Staudt LM; Wilson W
Br J Haematol; 2021 Jul; 194(1):83-91. PubMed ID: 33942292
[TBL] [Abstract][Full Text] [Related]
16. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
[TBL] [Abstract][Full Text] [Related]
17. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
18. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
[TBL] [Abstract][Full Text] [Related]
19. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray in a subset of South African patients with DLBCL.
Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
